Find and Pitch Jounalists, Get Your Story Covered

Tags: hardware robotics startups funding industrial robotics

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 8 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	What 3 layoff stories reveal about pharma’s troubles - 14 days ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 16 days ago Is anyone taking the world’s priciest drugs? - 21 days ago What pharma has learned from AI - about 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago The biggest questions hanging over pharma in 2024 - 8 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 3 standout digital innovations in pharma this year - 10 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago
3	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	M&A is ready to explode, and that’s good news for pharma layoffs - about 1 month ago As the GLP-1 market booms, other healthcare companies are cashing in - 2 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 3 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 6 months ago
4	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma’s fight against drug price reforms takes weird, desperate turn - 3 months ago
5	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Pharma has a misinformation problem — and execs could be on the hook - 8 months ago Pharma takes a gut check of microbiome drugs - 8 months ago What are pharma’s next blockbusters? - 9 months ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - 9 months ago Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline. - 10 months ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - 11 months ago
6	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	2024 - 8 months ago
7	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny - 9 months ago STAT+: FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19 - 11 months ago
8	Alexandra Pecci Pharma Voice Leading community for life sciences leaders. Washington, D.C. pharmaceuticalslife sciencescommunity building	5 noteworthy pharma AI investments in 2023 - 9 months ago The fortunes and flops of pharma M&A - 10 months ago The power of genomics-based healthcare remains largely untapped - 10 months ago
9	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Pfizer plans to depart BIO - 10 months ago
10	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says - 11 months ago

Journalists covering pharma industry